Citation Impact
Citing Papers
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
Rhizobium induces DNA damage in Caenorhabditis elegans intestinal cells
2019 StandoutNobel
Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O 2 -Regulated Prolyl Hydroxylation
2001 StandoutScienceNobel
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
2010 Standout
2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary
2011
Guidelines for the Primary Prevention of Stroke A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
2011
Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome
2008
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
Phytanoyl-CoA hydroxylase from rat liver: protein purification and cDNA cloning with implications for the subcellular localization of phytanic acid α-oxidation
1999
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
2010 Standout
Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
2018
Abdominal obesity and metabolic syndrome
2006 StandoutNature
Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease
2006
Dyslipidemia in type 2 diabetes mellitus
2009
Triglycerides and Cardiovascular Disease
2011
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
2010
Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis
2007
Inflammation and metabolic disorders
2006 StandoutNature
Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
1998 Standout
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy
2006
Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk
2009
Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
2013 Standout
Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome
2007
Effects of Torcetrapib in Patients at High Risk for Coronary Events
2007 Standout
Role for ELOVL3 and Fatty Acid Chain Length in Development of Hair and Skin Function
2004 StandoutNobel
Autophagy Links Inflammasomes to Atherosclerotic Progression
2012
The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
2020
The metabolic syndrome
2010 Standout
Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications
2007
Bariatric Surgery
2004 Standout
High-Density Lipoprotein as a Therapeutic Target
2007
Macrophages in the Pathogenesis of Atherosclerosis
2011 Standout
Interaction between high-density lipoproteins and inflammation: Function matters more than concentration!
2020
Evolution of the Lipid Trial Protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
2007
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
2009 Standout
Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis
2011
Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes
2010
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
2015 Standout
Statins and C‐Reactive Protein Levels
2007
The changing landscape of atherosclerosis
2021 StandoutNature
Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
2009
Guidelines for the Primary Prevention of Stroke
2010
Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study
2008
Biological Functions of Autophagy Genes: A Disease Perspective
2019 Standout
Cholesterol efflux pathways and other potential mechanisms involved in the athero‐protective effect of high density lipoproteins
2008
Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk
2010
Mechanisms of gallstone formation in women. Effects of exogenous estrogen (Premarin) and dietary cholesterol on hepatic lipid metabolism.
1991
Effects of Fibrates in Kidney Disease
2012
Diabetic Retinopathy
2012 Standout
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
2010 Standout
Diet–microbiota interactions as moderators of human metabolism
2016 StandoutNature
Safety Considerations with Fibrate Therapy
2006
Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
2007
Combined therapy in the treatment of dyslipidemia
2009
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
2009
Update on strategies to increase HDL quantity and function
2009
Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients
2014
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
2012
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
2008 Standout
Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials
2015
Combination statin–fibrate therapy: safety aspects
2008
Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development
2014
Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
2007
Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus – A pooled meta-analysis of randomized placebo-controlled clinical trials
2009
Gastric Surgery for Morbid Obesity
1990
Meta-Analysis of Comparison of Effectiveness of Lowering Apolipoprotein B Versus Low-Density Lipoprotein Cholesterol and Nonhigh-Density Lipoprotein Cholesterol for Cardiovascular Risk Reduction in Randomized Trials
2012
Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy
2013
A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
2010
Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention
2013
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
2008 Standout
Safety of Aggressive Lipid Management
2007
Progress and challenges in translating the biology of atherosclerosis
2011 StandoutNature
Insulin resistance and atherosclerosis
2006
Macrophage biology in development, homeostasis and disease
2013 StandoutNature
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
2008 Standout
Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis
2011 Standout
Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)
2012
Apolipoprotein A1 and B
2006
Diabetic retinopathy in sub-Saharan Africa: meeting the challenges of an emerging epidemic
2013
Drugs Targeting High-Density Lipoprotein Cholesterol for Coronary Artery Disease Management
2012
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
2013 Standout
Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment
2006
Fibrates Effect on Cardiovascular Risk Is Greater in Patients With High Triglyceride Levels or Atherogenic Dyslipidemia Profile: A Systematic Review and Meta-analysis
2010
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial
2007
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
2015 Standout
Combination therapy in dyslipidemia: Where are we now?
2014
Mortality Rates in Trials of Subjects With Type 2 Diabetes
2012
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy
2015 StandoutNobel
Dissecting racial bias in an algorithm used to manage the health of populations
2019 StandoutScience
Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction
2006 Standout
Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate
2009
Triglycerides and the Risk of Coronary Heart Disease
2006
Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
2014
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
2019 Standout
Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis
2015 StandoutNobel
Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study
2012
Regulation of Macrophage Functions by PPAR-α, PPAR-γ, and LXRs in Mice and Men
2008
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Guidelines for the Primary Prevention of Stroke
2014 Standout
Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome
2008
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
2018 Standout
Directed transposon Tn5 mutagenesis and complementation analysis of rhizobium meliloti symbiotic nitrogen fixation genes
1982 StandoutNobel
Management of type 2 diabetes and lipids: a critique of the NICE guidelines 2008
2009
Is There a Role for Fibrates in the Management of Dyslipidemia in the Metabolic Syndrome?
2007
Diabetic Dyslipidemia
2006
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
2011
Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
2008 Standout
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence
2015
Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes
2006
Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor
1996 StandoutScience
A general method for site-directed mutagenesis in prokaryotes
1981 StandoutNatureNobel
Visceral Obesity
2009
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
2016
Mechanisms of Diabetic Complications
2013 Standout
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
2012
Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis
2016
Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3)
2014
The Metabolic Syndrome
2008 Standout
Effects of Intensive Glucose Lowering in Type 2 Diabetes
2008 Standout
Assessment of omega‐3 carboxylic acids in statin‐treated patients with high levels of triglycerides and low levels of high‐density lipoprotein cholesterol: Rationale and design of the STRENGTH trial
2018
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus
2010 Standout
Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin‐controlled LDL cholesterol
2018
Uptake and metabolism of high-density lipoproteins by cultured rabbit hepatocytes
1990
Very long chain fatty acids in higher animals—A review
1995
Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
2017
Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study
2012
Works of M.J. Whiting being referenced
Prevalence and treatment of gall stones after gastric bypass surgery for morbid obesity.
1983
Effect of synthetic oestrogens and progestagens in oral contraceptives on bile lipid composition.
1983
Cholesterol crystal formation and growth in model bile solutions.
1983
Legume root nodule nitrogenase
1974
Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
2010
Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
2010
Bile acid synthesis and secretion by rabbit hepatocytes in primary monolayer culture: comparison with rat hepatocytes
1989
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
2005 Standout
Infantile Refsum's disease (phytanic acid storage disease): a variant of Zellweger's syndrome?
1984
Legume root nodule nitrogenase. Purification, properties, and studies on its genetic control.
1974